Evidence map›Paper›PMID 36017045›Full record

ReviewInternational journal of ophthalmology2022

Advances in the research of plant-derived natural products against retinoblastoma.

Jing-Chen Liu, Chun-Li Zhang, Kai-Ye Dong, Ming-Jun Li, Shu-Guang Sun, Cai-Rui Li

Open access · goldAbstract readReview
In one paragraph

Review in International journal of ophthalmology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Jing-Chen LiuDepartment of Ophthalmology, Jiangxi Provincial Hospital of Integrated Traditional Chinese and Western Medicine, the Fourth Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine, Nanchang 330003, Jiangxi Province, China.
Chun-Li ZhangDepartment of Ophthalmology, General Hospital of Southern Theatre Command, Guangzhou 510010, Guangdong Province, China.
Kai-Ye DongDepartment of Ophthalmology, the First Affiliated Hospital of Dali University, Dali 671000, Yunnan Province, China.
Ming-Jun LiSchool of Clinical Medicine, Dali University, Dali 671000, Yunnan Province, China.
Shu-Guang SunSchool of Clinical Medicine, Dali University, Dali 671000, Yunnan Province, China.
Cai-Rui LiSchool of Clinical Medicine, Dali University, Dali 671000, Yunnan Province, China.
Dali University · CNAffiliated Hospital of Jiangxi University of Traditional Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Retinoblastoma (RB) is a highly aggressive ocular tumor, and due to socioeconomic and medical constraints, many children receive treatment only in the metaphase and advanced clinical stages, resulting in high rates of blindness and disability. Although several approaches exist in the treatment of RB, some children with the disease do not have satisfactory results because of various factors. Plant-derived natural products have shown definite therapeutic effects in the treatment of various tumors and are also widely used in the study of RB. We review plant-derived natural products used in the study of anti-RB to provide ideas for the clinical application of these drugs and the development of new therapeutic drugs.

Indexed as

apoptosiscell cycledrug resistanceplant-derivedretinoblastoma

Identifiers

PMID36017045
PMCPMC9358176
OpenAlexW4288488776

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.